MX2021001503A - Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico. - Google Patents

Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico.

Info

Publication number
MX2021001503A
MX2021001503A MX2021001503A MX2021001503A MX2021001503A MX 2021001503 A MX2021001503 A MX 2021001503A MX 2021001503 A MX2021001503 A MX 2021001503A MX 2021001503 A MX2021001503 A MX 2021001503A MX 2021001503 A MX2021001503 A MX 2021001503A
Authority
MX
Mexico
Prior art keywords
nitric oxide
phosphodiesterase type
oxide releasing
inhibitor
nitrooxy
Prior art date
Application number
MX2021001503A
Other languages
English (en)
Spanish (es)
Inventor
Nicoletta Almirante
Stefania Brambilla
Laura Storoni
Francesco Impagnatiello
Elena Bastia
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of MX2021001503A publication Critical patent/MX2021001503A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2021001503A 2018-08-06 2019-07-31 Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico. MX2021001503A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18187482 2018-08-06
EP18210147 2018-12-04
PCT/EP2019/070597 WO2020030489A1 (en) 2018-08-06 2019-07-31 Nitric oxide releasing phosphodiesterase type 5 inhibitor

Publications (1)

Publication Number Publication Date
MX2021001503A true MX2021001503A (es) 2021-04-28

Family

ID=67539493

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021001503A MX2021001503A (es) 2018-08-06 2019-07-31 Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico.
MX2023012941A MX2023012941A (es) 2018-08-06 2021-02-05 Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023012941A MX2023012941A (es) 2018-08-06 2021-02-05 Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico.

Country Status (11)

Country Link
US (2) US11980618B2 (enExample)
EP (1) EP3833395A1 (enExample)
JP (2) JP7596257B2 (enExample)
KR (1) KR102836746B1 (enExample)
CN (2) CN112566670B (enExample)
AU (1) AU2019319004B2 (enExample)
BR (1) BR112021001950A2 (enExample)
CA (1) CA3108551A1 (enExample)
MX (2) MX2021001503A (enExample)
TW (1) TWI839375B (enExample)
WO (1) WO2020030489A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2969139T3 (es) * 2020-02-05 2024-05-16 Nicox Sa Composiciones para el tratamiento del glaucoma e hipertensión ocular
CN111217834B (zh) * 2020-02-21 2021-10-26 维眸生物科技(上海)有限公司 Rock激酶抑制剂的硝基氧衍生物
WO2022022669A1 (en) * 2020-07-30 2022-02-03 Biofront Therapeutics (Beijing) Co., Ltd. Dual-functional compounds and methods of use
WO2022090379A1 (en) 2020-11-02 2022-05-05 Nicox S.A. No-pde5 inhibitor for use in treating dry age-related macular degeneration, geographic atrophy and glaucoma-associated neurodegeneration
UY39509A (es) * 2020-11-09 2022-01-31 Ildong Pharmaceutical Co Ltd Compuestos inhibidores de la pde-5 y/o la pde-6 donantes de óxido de nitrógeno, y usos de estos
WO2023005180A1 (en) * 2021-07-30 2023-02-02 Biofront Therapeutics (Beijing) Co., Ltd. Dual-functional compounds and methods of use
US20250017928A1 (en) 2021-12-02 2025-01-16 Nicox Sa Ophthalmic pharmaceutical compositions containing a nitric oxide-releasing phosphodiesterase 5 inhibitor and method for the preparation thereof
PL4233867T3 (pl) 2022-02-24 2026-02-09 Nicox Sa Inhibitor PDE5 do zastosowania w leczeniu przedniej niedokrwiennej neuropatii nerwu wzrokowego

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149521A (ja) 1984-01-18 1985-08-07 Eisai Co Ltd 高眼圧・緑内障治療・予防用点眼剤
US4975428A (en) 1988-05-31 1990-12-04 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
CA2383466C (en) * 1999-09-16 2009-08-25 Tanabe Seiyaku Co., Ltd. Aromatic nitrogen-containing 6-membered cyclic compounds
KR100358083B1 (ko) 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
US20020168424A1 (en) 2002-07-31 2002-11-14 Dr. Mohsen Shahinpoor Nitric oxide (NO) donor+cGMP-PDE5 inhibitor as a topical drug for glaucoma
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
WO2008075152A1 (en) * 2006-12-15 2008-06-26 Pfizer Products Inc. 1- [4- (sulfonyl) -phenyl] -5- (benzyl) -ih-i, 2, 4-triazol derivatives as inhibitors of carbonic anhydrase for treating glaucoma or ocular hypertension
US7993616B2 (en) 2007-09-19 2011-08-09 C-Quest Technologies LLC Methods and devices for reducing hazardous air pollutants
CA2706082C (en) 2008-02-07 2017-10-03 Nicox S.A. Nitric oxide donor compounds
WO2010096320A2 (en) * 2009-02-18 2010-08-26 Bezwada Biomedical, Llc Controlled release of nitric oxide and drugs from functionalized macromers and oligomers
CN102498088A (zh) 2009-09-15 2012-06-13 帝斯曼知识产权资产管理有限公司 硝基氧基酯及其制备和用途
DK2512479T3 (en) * 2009-12-18 2016-06-06 Exodos Life Sciences Ltd Partnership Compositions for the treatment of peripheral vascular disease
EP2911656B1 (en) 2012-10-23 2020-12-02 Nicox SA Quinone based nitric oxide donating compounds for ophthalmic use
EP2826491A1 (en) 2013-07-15 2015-01-21 Nicox Science Ireland Ophthalmic compositions containing a nitric oxide donor
TW201625584A (zh) 2014-07-02 2016-07-16 諾華公司 茚滿及吲哚啉衍生物及其作為可溶性鳥苷酸環化酶活化劑之用途
ES2632808T3 (es) 2014-09-04 2017-09-15 Nicox Science Ireland Compuestos de carnosina donadores de óxido nítrico
CA2968010A1 (en) 2014-11-19 2016-05-26 Nicox S.A. Combinations of prostaglandins and nitric oxide donors
WO2016155906A1 (en) 2015-03-31 2016-10-06 Nicox S.A. Nitric oxide donating derivatives of fluprostenol
US10047047B2 (en) 2015-03-31 2018-08-14 Nicox S.A. Nitric oxide donating derivatives of latanoprost free acid
EP3088388A1 (en) 2015-04-30 2016-11-02 NicOx S.A. Nitric oxide donating derivatives of prostaglandins
KR102862562B1 (ko) 2015-11-16 2025-09-19 토파두르 파마 아게 포스포디에스테라제 억제제로서 2-페닐-3,4-디하이드로피롤로[2,1-f][1,2,4]트리아지논 유도체 및 이의 용도
EP3630769B1 (en) 2017-05-22 2025-07-02 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Also Published As

Publication number Publication date
US12642800B2 (en) 2026-06-02
TWI839375B (zh) 2024-04-21
CN119350347A (zh) 2025-01-24
AU2019319004B2 (en) 2025-04-24
WO2020030489A1 (en) 2020-02-13
CA3108551A1 (en) 2020-02-13
US20210322413A1 (en) 2021-10-21
BR112021001950A2 (pt) 2021-04-27
KR20210041596A (ko) 2021-04-15
TW202019491A (zh) 2020-06-01
JP2021533152A (ja) 2021-12-02
JP7596257B2 (ja) 2024-12-09
US20240245684A1 (en) 2024-07-25
KR102836746B1 (ko) 2025-07-21
CN112566670B (zh) 2024-11-12
JP2024150732A (ja) 2024-10-23
MX2023012941A (es) 2023-11-13
CN112566670A (zh) 2021-03-26
US11980618B2 (en) 2024-05-14
AU2019319004A1 (en) 2021-03-25
EP3833395A1 (en) 2021-06-16

Similar Documents

Publication Publication Date Title
MX2023012941A (es) Inhibidor de fosfodiesterasa tipo 5 con liberacion de oxido nitrico.
EP4529952A3 (en) Parp1 inhibitors
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
SA518400660B1 (ar) مركبات بيرميدين-2-يل أمينو -1h- بيرازول في صورة مثبطات لاستخدامها في علاج الاضطرابات التنكسية العصبيةlrrk2
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
EP4483882A3 (en) New methylquinazolinone derivatives
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
EP4656249A3 (en) Pyrazolopyrimidine derivatives as kinase inhibitor
EP4696380A3 (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
EP4275756A3 (en) Bipyrazole derivatives as jak inhibitors
TW201613875A (en) EGFR inhibitors, their preparation and their use thereof
TN2020000081A1 (en) Amino-methyl piperidine derivative as kinase inhibitor
MX2023002323A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
PE20170300A1 (es) Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
EP4603094A3 (en) New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild)
PH12019550217A1 (en) Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
PH12020550494A1 (en) Novel pyrazolo-pyrrolo-pyrimidine-dione derivatives as p2x3 inhibitors
EA201691402A1 (ru) Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
FR2974729B1 (fr) Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
EP4477222A3 (en) Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
PH12021551412A1 (en) Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
MX394860B (es) Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk).